Acne News

• Survey Outlines Pediatric Cosmetic Dermatology Trends A national survey highlighted scars, acne, and hyperhidrosis as the most commonly treated pediatric cosmetic conditions, with lasers leading as the most common treatment approach.
  Medscape Medical News, December 16, 2024
• LGBTQ+-Inclusive Language Missing in Acne Assessment An analysis of patient-reported outcome measures used for acne revealed gaps in the use of LGBTQ+-inclusive language, highlighting barriers to equitable care and assessment.
  Medscape Medical News, December 06, 2024
• SDPA 2024 Expert Discusses the ‘Four Pillars of Acne Pathogenesis’ “The average number of acne products used per patient is 2.53, but that’s also the average number of copays,” Shanna Miranti said.
  Medscape Medical News, December 03, 2024
• SDPA 2024 How to Calm Rosacea-Related Facial Erythema, Flushing Brimonidine 0.33% gel and oxymetazoline 1% cream typically start working within 30-60 minutes, according to Julie C. Harper.
  Medscape Medical News, November 22, 2024
• Study Compares Skin Toxicities of MEK Inhibitors in Children Dermatologic adverse events affected 97.8% of pediatric patients on MEK inhibitors, in a small retrospective single-center study.
  Medscape Medical News, November 20, 2024
• SDPA 2024 Why Topical Retinoids Are Key to Every Acne Regimen The drawbacks of retinoids involve the potential for irritancy, which can be concentration- and vehicle-dependent.
  Medscape Medical News, November 15, 2024
• Levonorgestrel IUDs Linked to Higher Skin Side Effects Levonorgestrel IUDs were associated with increased risks for acne, alopecia, and hirsutism in a study of FDA adverse event reports.
  Medscape Medical News, November 07, 2024
• Why a Diabetes Drug Fell Short of Anticancer Hopes Metformin, commonly used to treat diabetes, has been investigated for treating a range of cancer types in thousands of studies on laboratory cells, animals, and people.
  Knowable Magazine, October 14, 2024
• Study Evaluates Safety of BPO Products for Acne Of 111 products tested, 34% contained benzene levels above the FDA limit of 2 ppm.
  Medscape Medical News, October 10, 2024
• Pulsed Dye Laser an Option for Acne Treatment In a real-world study of PDL therapy in 15 adult women with recalcitrant acne, inflammatory and noninflammatory lesion counts were significantly reduced 3 months after treatment.
  Medscape Medical News, October 10, 2024
• Study Describes Skin Conditions in Down Syndrome Eczematous dermatitis was the most common skin condition diagnosed in patients with Down syndrome, according to a multicenter retrospective review.
  Medscape Medical News, October 07, 2024
• Study Reports Safety Data in Children on JAK Inhibitors The most frequently reported adverse events in children on a JAK inhibitor were blood and lymphatic system disorders, in a review of FDA and Canadian adverse event reports.
  Medscape Medical News, September 12, 2024
• Laser Treatment for Acne: Results From 100 Patients The protocol included three laser treatments spaced 3-4 weeks apart combined with medical therapy and other energy-based devices.
  Medscape Medical News, August 30, 2024
• iPLEDGE Reforms: Are Changes Imminent? Timeline Unclear The timeline for when an improved program might be in place remains unclear.
  Medscape Medical News, August 26, 2024
• Steps to Take for Diagnosing Cushing Syndrome Your patient's "round face" might be the first clue that he or she has Cushing syndrome, but there are other symptoms as well. How can you accurately diagnose the condition?
  Medscape Medical News, August 23, 2024
• What to Know About JAKne — JAK Inhibitor-Associated Acne Janus kinase (JAK) inhibitor-associated acne may be overlooked outside of dermatology, experts said.
  Medscape Medical News, August 22, 2024
• Upadacitinib Effective for Rare Disorder in Case Series A high dose of upadacitinib resulted in a meaningful clinical response in a study of several patients with long-standing recalcitrant granulomatous cheilitis.
  Medscape Medical News, August 02, 2024
• EULAR 2024 Taper, Dose Down, Discontinue: Striving for Less Steroid Use Now in the 75th year since the first presentation on the clinical use of glucocorticoids, what consensus has been reached in sparing their use to avoid their many potential adverse effects?
  Medscape Medical News, July 25, 2024
• GRAPPA 2024 Adverse Events Differ Between Two Second-Line Psoriasis Rxs Apremilast and deucravacitinib, oral small-molecule drugs approved for treating psoriasis, were linked to different adverse events, and adverse event profiles differed between men and women.
  Medscape Medical News, July 25, 2024
• New Benzoyl Peroxide Research: Reassuring Two new studies found no increased cancer risk and no difference in blood levels of benzene in users and nonusers of BP-containing acne products.
  Medscape Medical News, July 22, 2024